GENE ONLINE|News &
Antibody Drug Conjugates: The Next Big Thing in Cancer Therapy?
Cancer is the second most common cause of global deaths, accounting for approximately 10 million per year. It is estimated that in 2021 there will be an additional 1.9 million new cases in the US alone, with around 600,000 deaths. Cancer therapy has improved over the last decade, thanks to technological advances and research Progress. Here we take a closer look at one such significant advance, the antibody conjugated drugs (ADCs).
What are ADCs?
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
